Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Borja

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica|February 6, 2004
[Cholestatic hepatitis due to amoxicillin-clavulanic acid with positive re-exposure: Importance of proper terminology in drug vigilance]Javier Borja, David Rigau, Mario Souto
Lancet (London, England)|November 22, 2002
Fondaparinux versus enoxaparin for prevention of venous thromboembolismJavier Borja, Pere Olivella, Jorge Curto
Stroke|September 16, 2006
Prevention of stroke in patients with ischemic stroke or transient ischemic attackJavier Borja, Iñaki Izquierdo, Julián García-Rafanell
Medicina Clinica|October 21, 2003
[Adverse reactions to drugs among hospitalized elderly patients]Javier Borja, David Rigau, Iñaki Pérez, et al.
Lancet (London, England)|April 25, 2006
Controversies in cardiologyJavier Borja, Eva Arnáiz, Iñaki Izquierdo, et al.
JAMA|April 17, 2003
Clopidogrel and percutaneous coronary interventionsJavier Borja, Iñaki Pérez, Guillermo De la Cruz
Lancet (London, England)|March 15, 2006
Clopidogrel and metoprolol in myocardial infarctionJavier Borja, Olga García, Esther Donado, et al.
Journal of the American College of Cardiology|October 2, 2002
Enoxaparin after high-risk coronary stentingJavier Borja, Jorge Curto, Joaquin Campbell, et al.
Respiratory Medicine|January 14, 2011
COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA studyMarc Miravitlles, Iñaki Izquierdo, Alberto Herrejón, et al.
Arzneimittel-Forschung|February 27, 2010
Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I studyIñaki Izquierdo, Javier Borja, Sandra Rovira, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Enfermedades Infecciosas Y Microbiologia Clinica|February 6, 2004
[Cholestatic hepatitis due to amoxicillin-clavulanic acid with positive re-exposure: Importance of proper terminology in drug vigilance]Javier Borja, David Rigau, Mario Souto
Lancet (London, England)|November 22, 2002
Fondaparinux versus enoxaparin for prevention of venous thromboembolismJavier Borja, Pere Olivella, Jorge Curto
Stroke|September 16, 2006
Prevention of stroke in patients with ischemic stroke or transient ischemic attackJavier Borja, Iñaki Izquierdo, Julián García-Rafanell
Medicina Clinica|October 21, 2003
[Adverse reactions to drugs among hospitalized elderly patients]Javier Borja, David Rigau, Iñaki Pérez, et al.
Lancet (London, England)|April 25, 2006
Controversies in cardiologyJavier Borja, Eva Arnáiz, Iñaki Izquierdo, et al.
JAMA|April 17, 2003
Clopidogrel and percutaneous coronary interventionsJavier Borja, Iñaki Pérez, Guillermo De la Cruz
Lancet (London, England)|March 15, 2006
Clopidogrel and metoprolol in myocardial infarctionJavier Borja, Olga García, Esther Donado, et al.
Journal of the American College of Cardiology|October 2, 2002
Enoxaparin after high-risk coronary stentingJavier Borja, Jorge Curto, Joaquin Campbell, et al.
Respiratory Medicine|January 14, 2011
COPD severity score as a predictor of failure in exacerbations of COPD. The ESFERA studyMarc Miravitlles, Iñaki Izquierdo, Alberto Herrejón, et al.
Arzneimittel-Forschung|February 27, 2010
Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I studyIñaki Izquierdo, Javier Borja, Sandra Rovira, et al.
Pageof 3